RxSight Plans to Resume 2027 Guidance After Withholding 2026 Outlook

RxSight plans to resume issuing 2027 financial guidance after withholding a formal 2026 outlook. The company expects lower operating expenses in 2027 than in 2026, with restructuring savings taking effect that year and beyond.

RxSight has not provided formal guidance for 2026. It plans to resume guidance for 2027.

Management cited seasonality, competitive pressure from free-product trials, and internal disruption tied to restructuring and territory changes when discussing Light Adjustable Lens (LAL) performance. RxSight expects fourth-quarter LAL sales to be more in line with second-quarter levels.

The company is expanding its sales force and focusing on utilization across its U.S. installed base, practice integration, workflow and staff training.